Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.

"Competing interests The authors declare the following competing interests: S.T. received grant support from GSK, Bristol Myers Squibb (BMS), Janssen, Pfizer, Amgen, Roche and Genentech; consulting fees from BMS, GSK and Roche; and honoraria from BMS, Janssen, Amgen, Sanofi and Pfizer. A.M. received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. M.L.L. received research support from BMS/Celgene and Janssen; and honoraria from BMS/Celgene, Janssen, Gilead, AbbVie, AstraZeneca and Takeda. S.P. received consultancy honoraria from Janssen, BMS, FORUS and Apotex; study funding from GSK; and funding from BMS. D.W. received honoraria from Amgen, Antengene, BMS, FORUS Therapeutics, GSK, Janssen, Karyopharm, Pfizer, Sanofi and Takeda. M.P.C. received research support from BMS/Celgene and Janssen; and honoraria from BMS/Celgene, Janssen, Gilead, AbbVie, AstraZeneca and Takeda. R.K. received honoraria from Akcea Therapeutics, Amgen, BMS, Janssen, Merck, Sanofi, Celgene, Pfizer and Takeda; received research funding from Merck and Sanofi; and is a current equity holder in the private company Karyopharm. H.M. received advisory fees from Janssen, Takeda, Amgen, Pfizer, BMS, FORUS and Sanofi; received research funding from Janssen; and is supported by the early career award from Hamilton Health Sciences. I.O. participated in advisory boards for and received honoraria from Amgen, BMS, Celgene, FORUS Therapeutics, Janssen, Pfizer, Sanofi-Genzyme and Takeda; and received research funding from Janssen. J.S., A.K. and E.G. are employees of CMRG. D.R. received research funding and honoraria from, and is on the advisory board of, Janssen, BMS and Takeda; received research funding from Millennium Pharmaceuticals; and received honoraria from Amgen, Sanofi and GSK."

"This study was funded by GSK and sponsored by the Canadian Myeloma Research Group (CMRG). S.T. is supported by grants from the Canadian Institute for Health Research (grant no. 175267). Medical editorial support was provided by Articulate Science, LLC, and funded by the CMRG. We thank the patients who participated in this study as well as their caregivers and families, the members of the Data Monitoring Committee (P. Bedard, K. Yee and T. Panzarella (biostatistician)) and the following individuals from GSK: A. Palumbo (data interpretation and manuscript review) and A. Lowry (clinical trial management). Competing interests: The authors declare the following competing interests: S.T. received grant support from GSK, Bristol Myers Squibb (BMS), Janssen, Pfizer, Amgen, Roche and Genentech; consulting fees from BMS, GSK and Roche; and honoraria from BMS, Janssen, Amgen, Sanofi and Pfizer. A.M. received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. M.L.L. received research support from BMS/Celgene and Janssen; and honoraria from BMS/Celgene, Janssen, Gilead, AbbVie, AstraZeneca and Takeda. S.P. received consultancy honoraria from Janssen, BMS, FORUS and Apotex; study funding from GSK; and funding from BMS. D.W. received honoraria from Amgen, Antengene, BMS, FORUS Therapeutics, GSK, Janssen, Karyopharm, Pfizer, Sanofi and Takeda. M.P.C. received research support from BMS/Celgene and Janssen; and honoraria from BMS/Celgene, Janssen, Gilead, AbbVie, AstraZeneca and Takeda. R.K. received honoraria from Akcea Therapeutics, Amgen, BMS, Janssen, Merck, Sanofi, Celgene, Pfizer and Takeda; received research funding from Merck and Sanofi; and is a current equity holder in the private company Karyopharm. H.M. received advisory fees from Janssen, Takeda, Amgen, Pfizer, BMS, FORUS and Sanofi; received research funding from Janssen; and is supported by the early career award from Hamilton Health Sciences. I.O. participated in advisory boards for and received honoraria from Amgen, BMS, Celgene, FORUS Therapeutics, Janssen, Pfizer, Sanofi-Genzyme and Takeda; and received research funding from Janssen. J.S., A.K. and E.G. are employees of CMRG. D.R. received research funding and honoraria from, and is on the advisory board of, Janssen, BMS and Takeda; received research funding from Millennium Pharmaceuticals; and received honoraria from Amgen, Sanofi and GSK."